The contraceptive efficacy of Implanon®: A review of clinical trials and marketing experience

European Journal of Contraception and Reproductive Health Care

Volumn 13, Issue SUPPL. 1, 2008, Pages 4-12

  Graesslin, Olivier ^a   Korver, Tjeerd ^b  

^a Institut Mère Enfant Alix de Champagne   (France)

^b NV ORGANON   (Netherlands)

Author keywords

Clinical trials; Contraceptive efficacy; Etonogestrel; Implanon; Implant; Marketing experience

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; ETONOGESTREL;

BONE DENSITY; CLINICAL TRIAL; DEMOGRAPHY; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG TOLERABILITY; FEMALE CONTRACEPTIVE DEVICE; FEMALE FERTILITY; HORMONAL CONTRACEPTION; HUMAN; IMPLANT; LIPID METABOLISM; MENSTRUAL CYCLE; OUTCOME ASSESSMENT; PREGNANCY RATE; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

ADULT; CLINICAL TRIALS AS TOPIC; CONTRACEPTIVE AGENTS, FEMALE; DESOGESTREL; FEMALE; HUMANS; PRACTICE GUIDELINES AS TOPIC; PRODUCT SURVEILLANCE, POSTMARKETING;

EID: 40549124936     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.1080/13625180801942754     Document Type: Review

References (11)

1. Rai K, Gupta S, Cotter S. Experience with Implanon in a north-east London family planning clinic. Eur J Contracept Reprod Health Care 2004;9:39-46.
2. Lakha F, Glasier AF. Continuation rates of Implanon in the UK: Data from an observational study in a clinical setting. Contraception 2006;74:287-9.
3. Agrawal A, Robinson C. An assessment of the first 3 years' use of Implanon in Luton. J Fam Plann Reprod Health Care 2005;31:310-2.
4. Chaovisitsaree S, Piyamongkol W, Pongsatha S, et al. One year study of Implanon on the adverse events and discontinuation. J Med Assoc Thai 2005;88:314-7.
5. Bitzer J, Tschudin S, Alder J. Acceptability and side-effects of Implanon in Switzerland: A retrospective study by the Implanon Swiss Study Group. Eur J Contracept Reprod Health Care 2004;9:278-84.
6. Implanon® (etonogestrel implant). Full Prescribing Information. Oss, The Netherlands: NV Organon (part of Schering-Plough) 2005.
7. Makarainen L, van Beek A, Tuomivaara L, et al. Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant. Fertil Steril 1998;69:714-21.
8. Davies GC, Feng LX, Newton JR, et al. Release characteristics, ovarian activity and menstrual bleeding pattern with a single contraceptive implant releasing 3-ketodesogestrel. Contraception 1993;47:251-61.
9. Harrison-Woolrych M, Hill R. Unintended pregnancies with the etonogestrel implant (Implanon): a case series from postmarketing experience in Australia. Contraception 2005;71:306-8.
10. Wenzl R, Van Beek A, Schnabel P, et al. Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon. Contraception 1998;58:283-8.
11. McCann MF, Potter LS IV. Efficacy and pregnancy outcomes. In McCann MF, Potter LS, eds. Progestin-only oral contraception: a comprehensive review. Contraception 1994;50(Suppl.1):S34-S53.